Five policy movements

Ophthalmology entered the national fund audit.

The 2026 national medical-insurance fund inspection No.4 (audit framework 医保发〔2026〕4号, 2 February) launched on 14 May, naming ophthalmology among fifteen priority inspection domains, up from the seven set in February. This is the convergence in concrete form: the audit timeline runs straight into the late-May procurement turnover, so compliance readiness and procurement readiness become one workstream rather than two.

A five-year supervision plan made audit a standing fixture.

The five-year medical-insurance fund supervision action plan (《监督检查五年行动计划（2026—2030）》, 13 May) targets full on-site inspection coverage of designated institutions within the period. Audit exposure is structural, not a single campaign; traceability becomes a recurring cost line, not a one-off.

First-wave IOL agreements turned over.

The first wave of fourth-batch national IOL procurement (national tender GH-HD2023-1; Guangxi, Guangdong and Shenzhen, from 30 May 2024) reached its two-year mark around 30 May 2026, with Beijing to 28 June; by 31 May, no IOL-specific renewal or transitional notice had been published. The details of the expiry, the staggered provinces, the impairment already booked, and the likely magnitude are the subject of this month’s standalone IOL analysis. For the monthly picture, the point is timing: the turnover lands inside the audit window that opened the same fortnight.

The device-renewal rulebook became visible.

The coronary stent second-round renewal (national tender GH-HD2026-1) opened on 20 May 2026, with 27 of 30 products selected across 15 enterprises, 4,468 hospitals filing roughly 2.73 million units a year, and the cycle extended to 30 June 2029. Its design, inquiry-based pricing, volume tied to bid position, and an explicit anti-involution principle are the template a future IOL renewal is most likely to reference. That the mechanism now exists for devices yet remains unextended to lenses is the policy-execution gap in its current form.

The drug-formulary plan codified a quantified graduation rule.

The formal 2026 formulary work plan (NHSA, 31 May; applications 1–10 June) states that negotiated drugs in the catalogue for eight years, with in-insurance sales above RMB 300 million, take a uniform 10 per cent cut and move to routine catalogue management. OphthalLogix’s reading: this is the first national medical-insurance rule to pair a time threshold with a sales threshold, a quantified logic that a future IOL renewal framework may borrow.

Presentation May 2026 Delta Log

264KB ∙ PDF file

Download

Download

May 2026 Delta Log

252KB ∙ PDF file

Download

Download

What did not move

No material movement this month in the following: an IOL-specific renewal or second-round scheme (still unpublished); the county inspection schedule under the April cataract enforcement directive No.134 (national directive 国卫办医政函〔2026〕134号, expected from the third quarter); the Tianjin tiered price mechanism (final version not yet issued); DRG/DIP 3.0 ophthalmology grouping (not yet published); the Guizhou sunshine-listing enforcement (effective 1 June, no enforcement action recorded as of cut-off); and no material IOL-specific listed-company disclosure. Existing frameworks remain in force.

Key Implications

For international device manufacturers and the teams managing China market access, May’s signal is convergence, not a single event. The renewal mechanics are now visible: inquiry-based pricing, a moving ceiling, volume tied to bid position, so IOL renewal planning can proceed against a known template; the open variable is timing, not method. Because the fund audit reached ophthalmology in the same month the procurement cycle turned over, compliance readiness and commercial readiness are now on the same timeline, not two. Premium lenses carry the asymmetric exposure, where an agreement has turned over without renewal, volume management bears on multifocal and EDOF lines first.

Subscribe now

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content. intelligence@ophthallogix.com · www.ophthallogix.com

Subscribe now

The expiry is staggered, not national

The fourth national volume-based procurement round for intraocular lenses ran a two-year cycle, executed province by province. The first wave, Guangxi, Guangdong and Shenzhen, live from 30 May 2024, reached its two-year mark around 30 May 2026. Beijing follows on 28 June; Hunan on 30 June. The exposure is sequential, and the first-wave provinces carry it first.

What is missing is the administrative sequence that normally precedes expiry. A provincial medical security bureau confirms volume commitments, price schedules and signatories before the prior agreement ends. For the first-wave provinces, none of that has appeared. The most recent national platform notice, dated 30 April 2026, was a routine product-maintenance note, no renewal content, thirty days before the first agreements lapsed. The silence is the signal.

The renewal playbook now exists

The contrast is sharp because the renewal mechanism is no longer hypothetical. On 20 May 2026, the second-round renewal of coronary stent procurement opened in Tianjin (采购文件编号 GH-HD2026-1). Fifteen manufacturers tendered thirty products; every bidder won, and twenty-seven products were tentatively selected. The design is instructive: prices set by inquiry rather than competitive undercutting, procurement volume tied to price tier, and an explicit principle of stabilising clinical supply, protecting quality and curbing involution. Newly approved products may apply for supplementary selection mid-cycle. This is the device renewal playbook, demonstrated on the first device category China ever procured at a national scale.

A provincial template exists as well. The Inner Mongolia transitional procurement notice No. 255 (内药采中心字 [2025] 255号), issued on 17 December 2025, kept expired alliance device agreements in place at their original prices and extended the transitional category to 30 June 2026 on a single, light-touch notice. Bridging an expiry is administratively trivial. It has not been issued for intraocular lenses.

The gap

This is the policy-execution gap in its clearest form, not the absence of a precedent, but a complete one, demonstrated on coronary stents and available as a provincial transitional tool, that has not been extended to intraocular lenses. The coronary rules will not transfer line by line; a stent and a trifocal lens are different products, but the regulator now holds a worked, recent answer to the question the IOL provinces are asking. The information asymmetry is the cost. The first-wave provinces had seventeen days to improvise what Inner Mongolia had prepared five and a half months in advance.

What the books already show

The corporate record already prices in a move. In February 2026, Haohai Biotech (688366) booked a goodwill impairment of RMB 141 million against its IOL distribution subsidiary, citing an expected second-round price cut in the first half of 2026. The accounting was completed in February; the first half ends on 30 June. A price event recognised in the books must now either materialise or force a revision.

How far prices move

On magnitude, OphthalLogix’s reading is that the renewal discount is more likely to be mild than steep, a deeper cut is the main downside risk, not the central case. The first round already compressed IOL prices by around 60 per cent. The structural floor has been tested, and the regulator’s stated direction against involution works against another deep cut. A category-specific mechanism, with room for a separate premium track, fits the policy direction better. Independent market analysis points the same way.

What hospitals do in the interval

The more useful question is what hospitals do in the interval. The likeliest response, in our assessment, is continuity: most will keep ordering selected lenses at the original prices while managing volume down, rather than freeze procurement or switch to higher non-selected listings. Cataract surgery is elective. Admissions teams confirm lens model and price before a patient enters the ward, not in theatre, so the friction point is the scheduling decision, not the operating table. The rational response to a short, uncertain window is to control incoming volume, not to stop, and not to expose patients to a sudden out-of-pocket increase. Hospitals take their lead from the policy file; with a new framework expected within weeks, few will step outside it and risk unwinding the position once it arrives.

Key Implications

For teams managing China device portfolios, this is not yet a pricing decision; it is a forecasting and reporting gap. The renewal magnitude cannot be locked, but the probability distribution has narrowed: a mild reduction, a category-specific design, and a premium segment defended on clinical grounds. Distributors cannot default to the old price as a commercial choice; provincial platform configuration governs what can be ordered, so operational risk concentrates wherever a platform closes the prior-agreement entry before a transitional notice arrives. The audit overlay tightens the timing; the 2026 national medical insurance fund inspection programme, set out in the supervision notice of 2 February 2026 and formally launched on 14 May 2026, with ophthalmology among its priority areas, so the compliance window and the procurement window now coincide. Watch for a national or first-wave transitional notice through early to mid-June; its absence past Beijing’s 28 June expiry would carry the vacuum into a second wave.

— The OphthalLogix Intelligence Team

Subscribe now

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content. intelligence@ophthallogix.com · www.ophthallogix.com

China has just done something it has been signalling for two years: the second renewal of national high-value device VBP is a temperate one. For ophthalmology, the awkward part is what was not published alongside it.

On 13 May 2026, the National Organisation Joint Procurement Office of High-Value Medical Consumables published the second-round renewal procurement document for coronary stents — file number GH-HD2026-1 (国家组织冠脉支架集中带量采购第二轮接续采购文件，编号GH-HD2026-1). On 20 May, the tender opened in Tianjin. The numbers are public: 15 companies bid, 30 products were submitted, all 15 companies were selected, 27 products won. 4,468 hospitals filed annual demand for approximately 2,726,093 alloy stents and 12,980 stainless-steel stents. The procurement cycle was extended through 30 June 2029.

Three details from GH-HD2026-1 matter for any audience watching renewal mechanics rather than the stent market itself.

First, the maximum effective bid price for alloy stents was raised from 848 RMB to 949 RMB per unit, an increase of approximately 11.91%. This is the first upward adjustment of a ceiling price in the history of high-value device VBP. Stainless-steel stents were added as a parallel category at 848 RMB. The signal is not subtle: after five years of one-way price pressure, the framework now has formal room for moderate price recovery.

Second, the renewal mechanism is an inquiry-based selection (询价模式) with tiered volume allocation. A bidder offering at or below the maximum effective price is selected; the proximity of its bid to the renewal reference price determines the share of contracted volume it receives. This replaces a regime in which the lowest bidder took disproportionate volume. The downside risk to the bidder is bounded by the published ceiling; the upside is governed by where they choose to land within the corridor.

Third, products newly approved during the procurement cycle may apply for supplemental selection under defined rules. Innovation has a stipulated re-entry path within the three-year cycle, rather than waiting for the next round.

These three pieces, a ceiling that can move up, tiered volume tied to bid position, and a window for new entrants, are the renewal methodology China has now published twice (coronary stents 2022 and 2026) and once for orthopaedic joints (GH-HD2024-1, executed from 10 November 2024). For spinal implants, the second-year arrangement was handled differently: a renewal-by-agreement model in which existing winning prices were extended through bilateral protocol updates rather than a new tender.

Subscribe now

What is missing, and why is the timing awkward

The first batch of provincial IOL procurement agreements expires on 30 May 2026 for Guangdong, Shenzhen and Guangxi. The main national wave expires on 30 June 2026. As of 25 May, no renewal procurement document, no transitional notice, and no equivalent of GH-HD2026-1 has been published for intraocular lenses.

The 2026 work plan published by the National Healthcare Security Administration explicitly includes “the period-end renewal for intraocular lenses and sports medicine consumables” as a 2026 task. The intention is on the record. The instrument is not. This is the policy-execution gap that defines the next two weeks for IOL stakeholders.

For the coronary stent renewal, the gap between document publication (13 May) and contract expiry varied by region but was measured in weeks, not days. For IOL, the equivalent gap is now down to five days for the first batch of provinces and roughly five weeks for the main wave.

Two paths the renewal could take, and a third that is more likely

There are two published precedents and two distinct mechanics.

The coronary-stent and joint path is a published renewal procurement document with a new bidding round, a tiered ceiling, and a redefined cycle. It restarts price formation under a refreshed methodology.

The spinal-implant path is a renewal-by-agreement: provincial-level execution notices extend the existing winning prices into a second contract year under the original framework, without a new national tender. Guangdong’s second contract year for spinal implants ran from 15 March 2024 to 14 March 2025. Provincial extension notices in Hebei, Jiangxi and elsewhere followed in late 2024.

Neither precedent is likely to be a clean fit for IOL. The clinical product taxonomy makes a pure stent-style approach awkward: coronary stents resolve into two categories, alloy and stainless steel. IOLs resolve into at least six functionally distinct groups (monofocal non-toric, monofocal toric, bifocal, EDOF, trifocal, premium aspheric, and others). Within each group, post-operative outcomes are more tightly determined by product category than by manufacturer-level material differentiation. A toric monofocal IOL, regardless of brand or material, is expected to deliver a toric monofocal outcome; differentiation tends to operate at a second tier rather than the primary one. A single tiered-volume formula stretched across all six categories would either over-protect commodity groups or under-protect the premium ones.

The more probable structure, and this is OphthalLogix’s assumption, not a published rule, is a hybrid: functional grouping as the primary axis, with stent-style inquiry-based selection and tiered volume operating within each functional group. The renewal could publish six (or more) parallel price corridors, each with its own ceiling, reference price, and volume tiers. That structure would let monofocal categories compete on price-stability-versus-outcome inside one corridor, and premium categories (EDOF, trifocal) compete inside another, without forcing the two to share a single curve.

If this hypothesis is approximately right, the question for IOL manufacturers becomes which corridor matters most to them, and how aggressively they expect competitors inside that corridor to bid.

What price recovery looks like, qualitatively

Coronary stents are a single data point. The direction is clear (modest upward adjustment of the ceiling, with selection mechanics designed to discourage destructive bidding), but the magnitude, +11.91% on the alloy ceiling, does not translate mechanically to IOL.

On the supply side, domestic IOL manufacturers have absorbed approximately two and a half years of post-VBP price compression. Some categories retain operating margin headroom; some do not. Where the margin is intact, OphthalLogix expects domestic bidders to opt for a modest downward bid within the corridor to secure inclusion and volume rather than reach for an aggressive cut. Where margin is already thin, holding the line on price is the more likely strategy.

Multinational manufacturers carry brand equity, post-operative outcome stability, and surgeon familiarity into the renewal. In categories where reimbursement permits comparable corridors, a moderate downward adjustment to defend or expand volume, rather than a defensive hold, is the more rational position. The Chinese IOL volume base remains the largest single market opportunity for premium implants globally; entering the selection list at a moderate concession protects future positioning more efficiently than sitting outside it.

The renewal, when it arrives, will be a temperate one. Decisive further price compression beyond the first-round 60% average reduction is unlikely. Volume reallocation between domestic and multinational bidders, and within product categories, is where the real competitive action will sit.

What hospitals do in a transitional window

If the renewal framework arrives before 30 May or 30 June, none of this matters operationally. If it does not, hospital procurement faces a short window in which the previous contracts have lapsed, but no replacement framework is in effect.

Based on prior cataract surgical practice in tertiary centres, the dominant institutional response is to continue routine ordering under the existing framework prices in reduced batches, rather than to suspend cataract surgery. Procurement teams typically contact provincial medical insurance bureaus first; in the absence of new guidance, the operational default is to maintain throughput. Excess inventory accumulated in this window is usually returnable to suppliers once a new framework is published.

Where the operational picture diverges is at the premium end. For monofocal and bifocal categories, the substitution set is broad; if a specific SKU becomes briefly unavailable, alternatives are available within a comparable price band, and surgeons can resolve substitution in pre-admission planning. For the trifocal and EDOF categories, the substitution set is narrower. The realistic options, in approximate descending order of frequency: postpone the elective procedure, substitute with a bifocal at the patient’s consent, or, rarely, proceed with the original implant under patient self-payment. The last option is operationally weak, because once a new framework publishes a lower official price than what the patient paid out-of-pocket, the patient-relationship cost outweighs the case revenue.

None of this is improvised at the operating table. Cataract surgery is elective and short-cycle; the IOL is confirmed at admission, sometimes at the outpatient stage. Substitution decisions are made before the patient is on the table, not during the procedure.

What investors and market-access teams should be doing this week

For listed domestic IOL manufacturers (Eyebright Medical 688050, Haohai Biotech 688366), the renewal mechanics, not the headline price, will determine the 2027 revenue trajectory. Whether the renewal uses the stent-style inquiry mechanism or the spinal-style agreement extension changes, which scenarios should be modelled?

For multinational market-access teams, the present week is for scenario design rather than execution. Three pricing scenarios, moderate hold, moderate downward adjustment to secure tiered volume, and defensive aggressive cut to expand share, should each have a defined trigger condition tied to whichever framework variant is published.

For hospital procurement teams, the conservative operational default holds: maintain existing throughput at existing prices, in reduced batches, with supplier return arrangements clarified for any accumulated inventory.

A line worth holding

The most reliable thing that can be said about this moment is that the methodology now exists in published form. Three iterations of stent renewals, one orthopaedic renewal, and one spinal agreement extension. The instruments are on the shelf. The IOL framework has not been published yet. Whether the next two weeks close that gap, or whether the first batch of provinces operate in a brief documentary vacuum, will be visible to anyone watching the procurement office website.

Either outcome is informative. The publication-or-silence of the next two weeks is the most useful single data point an IOL stakeholder will get this quarter.

Subscribe now

This content is for informational purposes only and does not constitute legal, regulatory, investment, medical, or commercial advice. China's healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content. Where this content includes working assumptions or hypotheses about future policy mechanics, these are framed as assumptions, not predictions of fact, and should be retested against the actual published framework.

On 14 May 2026, China’s National Healthcare Security Administration (NHSA, 国家医疗保障局) formally launched its annual medical insurance fund audit programme, with ophthalmology named among 15 priority inspection domains. This is not a standalone event. It arrives within the same 30-day window as the first intraocular lens (IOL) procurement agreement expiry dates and the binding force of two National Health Commission (NHC, 国家卫生健康委员会) cataract surgical standards issued 17 days apart in April. The convergence creates a compliance crossroads that will separate institutions operating within the framework from those that have not yet built one.

Signal One: Ophthalmology Enters the Audit Spotlight

The NHSA’s 2026 audit framework was first published on 2 February 2026 in the Notice on Medical Insurance Fund Supervision Work No.4 (NHSA Notice 医保发〔2026〕4号). That document named seven priority clinical domains: orthopaedics, oncology, diagnostic testing, ophthalmology, oral medicine, general surgery, and neurology. By the time the formal launch took place in Changsha on 14 May, the scope had expanded to 15 domains, adding cardiology, haemodialysis, psychiatry, and others.

The expansion is the signal. Ophthalmology has moved from peripheral surveillance to a named enforcement priority, a trajectory consistent with the escalation pattern observed in orthopaedics between 2022 and 2024, where audit naming preceded a sustained compliance campaign.

The policy-execution gap is significant. The NHSA has declared ophthalmology a priority, but the specific audit criteria for the speciality remain unpublished. The four-point data reconciliation that audit teams will apply, including surgical volume, IOL procurement records, hospital information system entries, and insurance reimbursement claims, has been confirmed through prior audit precedents in other specialities and through a publicly reported enforcement action against Xinxing Jingliang Eye Hospital in Guangdong Province in 2025, where procurement-usage-billing inconsistencies were the primary finding. But the thresholds, tolerance margins, and scoring methodology for ophthalmology-specific audits have not been disclosed.

This opacity is itself a commercial variable. Institutions that have already built electronic traceability systems for IOL procurement, usage, and billing are positioned to absorb the audit. Those that have not, and the compliance capability gap between major public tertiary hospitals and smaller private or county-level institutions is well documented, face a binary outcome: rapid system deployment or enforcement exposure.

Signal Two: IOL Procurement Agreements Approach Expiry

The fourth national volume-based procurement round for IOL established two-year agreement periods that begin expiring from late May 2026. Guangdong, Shenzhen, and Guangxi are among the earliest. No renewal framework, second-round procurement plan, or transitional arrangement has been published by the NHSA or the National Joint Procurement Office as of 19 May 2026.

OphthalLogix has tracked this procurement vacuum since the 04–10 May scan cycle (see prior analysis). The relevance to the audit signal is direct: audit teams will assess whether hospitals have fulfilled their agreement volume commitments before expiry. Institutions that under-procured selected products, or that diverted volume toward non-selected products without proper documentation, face simultaneous scrutiny from both the procurement compliance review and the insurance fund audit.

The absence of a published renewal timeline creates a secondary problem. Hospitals cannot demonstrate forward compliance intent, a factor that audit teams may weigh when assessing institutional risk profiles. The silence from the procurement authority is not neutral; it is an operating condition that compounds compliance exposure.

Signal Three: NHC Surgical Standards as the Audit Baseline

On 13 April 2026, the NHC published the National Standard for Adult Cataract Surgery No.117 (国卫办医政函〔2026〕117号). Seventeen days later, on 29 April, it issued a county-level enforcement directive to 24 provinces (国卫办医政函〔2026〕134号). The 17-day sequencing was a policy-execution gap signal: the NHC had already assessed that county-level compliance was insufficient to self-organise and required a directed enforcement mandate.

These two standards now serve as the operational baseline against which audit findings will be measured. Before April 2026, auditors checking ophthalmology departments had no single national standard to benchmark against; local protocols, institutional guidelines, and clinical custom filled the gap. The NHC has closed that gap. Every cataract surgery performed in a public hospital in China now has a published procedural standard, and the standard is binding.

The practical consequence: the audit programme that launched on 14 May has a compliance reference document that did not exist five weeks earlier. The standards normalise surgical workflow, IOL selection documentation, postoperative follow-up protocols, and, critically, traceability requirements for implanted devices. An audit team arriving at a hospital in June 2026 will check the institution’s alignment with these standards. An audit team arriving in March 2026 could not have done so.

The Commercial Intersection

The convergence of these three signals creates differentiated pressure depending on institutional type.

For established public tertiary hospitals with existing compliance infrastructure, the audit is an administrative exercise. These institutions have invested in electronic procurement tracking, standardised surgical workflows, and insurance billing separation between reimbursable and self-pay procedures. The NHC standards codify what they already practise. The audit confirms their framework rather than disrupting it.

For private ophthalmology chains and county-level hospitals where compliance systems are less mature, the 30-day window is a forcing function. The publicly reported enforcement actions against multiple branch hospitals of leading private chains in 2025, covering overbilling, duplicate charges, excessive testing, and procurement-billing mismatches, demonstrate that scale does not insulate against compliance failures at the institutional level. The audit’s “flying inspection” format (unannounced, data-driven, no prior notification) removes the preparation buffer that structured inspections traditionally provided.

For device companies managing hospital relationships, the implication is channel risk stratification. The compliance status of a hospital customer is now a commercial variable, not because the device company is liable for the hospital’s billing practices, but because a hospital under audit enforcement may suspend procurement, lose insurance reimbursement qualification, or face volume quota reductions that directly affect device sales forecasts. The distinction between a hospital that treats the audit as routine confirmation and one that treats it as crisis management is a distinction that belongs in commercial planning.

Key Implications

China’s 2026 national medical insurance audit programme, launched on 14 May, names ophthalmology among 15 priority domains, an operational expansion from the seven specified in the February 2026 framework No.4 (NHSA Notice 医保发〔2026〕4号). The audit coincides with the first IOL procurement agreement expiry dates (late May 2026) and the newly binding NHC cataract surgical standards No.134 (国卫办医政函〔2026〕117号 and 134号, April 2026). For institutions with a mature compliance infrastructure, this convergence is confirmation. For those without, it is a deadline. Companies with hospital portfolios spanning both categories should be modelling the difference.

— The OphthalLogix Intelligence Team

Subscribe now

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.

intelligence@ophthallogix.com · www.ophthallogix.com

China’s national IOL procurement agreement expires on or around 30 May 2026. No renewal framework has been published. With fewer than three weeks remaining, enterprises and hospitals are operating without a price floor, a volume commitment, or a timeline, a policy-execution gap with no direct precedent in the device VBP programme.

The Agreement Ends. No One Has Said Anything.

China’s 4th national VBP round covered intraocular lenses with a two-year procurement cycle. Provinces began executing the agreement from mid-2024. The first wave expires at the end of this month.

Guangdong and Shenzhen: 30 May 2026. Guangxi: 29 May 2026.

As of 14 May, the National Healthcare Security Administration and the National Joint Procurement Office have published no renewal framework, no second-round procurement document, and no transitional arrangement for any of these provinces.

That silence is the signal.

In Normal Cycles, This Does Not Happen.

Year-2 annual renewals follow a documented pattern. Provincial medical security bureaux issue notices before the prior-year agreement lapses. The process is administrative: confirm volumes, sign three-party agreements, and continue. Guangdong issued its Year-2 renewal notice in June 2025, technically after the Year-1 period had ended, but with the system configured to treat continuation as the default.

The 6th national VBP round, covering drug-coated balloons and urological devices, ran to a clear clock. Procurement documents were published in late December 2025. Results announced 14 January 2026. Implementation expected in May 2026.

IOL is different. The two-year cycle ends. There is no announced second round. There is no transitional notice. The contrast is not subtle.

One Company Has Already Adjusted Its Balance Sheet.

In February 2026, Haohai Biotech (688366) recorded a goodwill impairment of RMB 141 million against its IOL distribution subsidiary. The stated rationale: an expected second-round price reduction in H1 2026.

The company adjusted its accounts based on a round-2 pricing expectation. That expectation has not been confirmed. H1 2026 is now five weeks from ending. The policy has not moved.

This is not a criticism of Haohai’s accounting judgment. It is an illustration of where the gap sits: between enterprise planning horizons and the actual pace of policy formation.

What the Next 16 Days Could Produce.

Three triggers are worth watching.

An NHSA or Joint Procurement Office announcement of a second-round framework or a national transitional arrangement. If nothing has been published by around 20 May, the working assumption shifts: national silence likely means provinces will handle the transition independently, with all the variation that implies.

Provincial transition notices from Guangdong, Shenzhen, or Guangxi. Precedent exists, Inner Mongolia’s Medical Procurement Centre issued a transitional procurement notice No.255 (内药采中心字 [2025] 255号, 17 December 2025) for provincial alliance VBP devices whose agreements had lapsed, extending original VBP results until June 2026. The IOL provinces have not followed suit.

Voluntary disclosures from listed companies. Haohai Biotech and AiBo Medical have reporting incentives to update their round-2 expectations. A change in tone, or the absence of one, is itself a data point.

OphthalLogix Analyst Note: Not all provinces face the same pressure at the same time. Several: Beijing, Tianjin, Yunnan, Hunan, and Hubei, have agreements running through June or July 2026, providing a buffer of four to eight weeks beyond the first-wave expiry. Whether that buffer is used to issue a unified national framework or compresses the same uncertainty into a later window will determine whether this is a managed transition or a rolling disruption.

Key Implications

The absence of a renewal framework is not a procedural delay; it is the signal itself. Enterprises with selected IOL status cannot confirm post-30 May pricing or volume commitments. Hospitals in Guangdong, Shenzhen, and Guangxi face a procurement decision point without a governing framework. International device manufacturers reporting China IOL market access status to regional or global headquarters have no confirmed timeline to communicate. The policy-execution gap will begin producing measurable effects, controlled volume reduction, informal procurement continuation, or provincial-level patchwork arrangements, within days of 30 May.

Further Detail

The provincial expiry matrix, renewal pricing scenario analysis, clinical-execution logic, and 30-day action checklist by stakeholder function are covered in the Commercial Execution Brief for this signal.

Applications by email: intelligence@ophthallogix.com, state your name, role, organisation and LinkedIn profile. Restricted distribution.

— The OphthalLogix Intelligence Team

Subscribe now

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be independently verified before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content. intelligence@ophthallogix.com · www.ophthallogix.com

China’s 2026 national drug formulary consultation opened on 9 May. It advances the annual cycle by approximately one month, introduces pre-submission rights for drugs with completed technical review, and formally links commercial insurance coverage to basic formulary eligibility. None of this is the most consequential signal in the document for ophthalmology. The sharper question is what happens when anti-VEGF drugs that entered the formulary in 2017 now sit at the 8-year threshold where pricing can lock in permanently, and whether the revolving door between commercial and basic insurance that NHSA has just formalised on paper can actually turn in practice.

What Pre-Submission Actually Does

The mechanism is straightforward in design. Drugs that have completed technical review at NMPA but have not yet received formal approval may now file formulary applications before their registration certificate is issued. Under previous rules, the cut-off was formal approval before 30 June. The 2026 draft shifts the cut-off to the date the formal plan is published, expected by the end of May. [NHSA consultation document, 9 May 2026]

NHSA states the overall cycle will start approximately one month earlier than in prior years. Industry analyst Guo Xinfeng (CEO, Nanjing Evidence Biosciences) frames the individual drug-level impact more precisely: by removing the forced wait for formal approval, the pre-submission mechanism could compress the approval-to-formulary timeline for an individual drug by an estimated three to six months. [Third-party expert estimate, attributed]

A policy-execution gap is already visible. “Completion of technical review” is the eligibility threshold, but companies must self-certify their NMPA review status, and the preparation window between the consultation closing (15 May, 17:00 Beijing time) and the formal submission window (June–July) is compressed to days, not weeks. For companies near the eligibility boundary, this is an immediate operational question.

The Commercial Insurance Dual-Track: Design and Execution

The 2026 consultation adds three new application pathways for drugs not yet in the basic formulary. The most significant: drugs already listed on China’s commercial health insurance innovative drug list may now formally apply for basic formulary inclusion. The reverse pathway, commercial insurance list drugs applying again when new indications are approved, is also formalised. [NHSA consultation document, 9 May 2026]

The institutional logic is deliberate. Products priced above the “protect the basics” threshold of basic insurance enter commercial insurance coverage first; clinical utilisation evidence accumulates; the product migrates to basic formulary later at adjusted pricing. The 2026 draft has codified this architecture in both directions.

The first commercial health insurance innovative drug list launched in 2025, covering 19 drugs, CAR-T therapies, rare disease treatments, and oncology targeted agents. No ophthalmology drugs were included. [NHSA official Q&A, 9 May 2026]

The execution record from that first version is unambiguous. Implementation was impeded by a structural constraint: drug company discounts cannot appear on hospital invoices; insurers can only reimburse at invoice price; compliant discount-return mechanisms via third-party administrators remain legally unsettled. Hospital procurement committees have not moved quickly. Physician prescription incentives within hospital performance management systems have not been adjusted. [NHSA official Q&A; industry participant assessments reported in specialist press]

This is a policy-execution gap operating at the mechanism level, not the regulatory intent level. The revolving door exists in the legal text. The practical flow through it is blocked by infrastructure constraints that formal rules alone cannot resolve.

One additional mechanism formalised in the 2026 consultation: competitive drugs entering the formulary will face a price warning system. Hospital procurement prices exceeding 1.8 times the payment standard receive a yellow label; those exceeding three times receive a red label. [NHSA official Q&A, 9 May 2026] Previously applied in provincial device procurement, this price-signalling logic is now national in scope for formulary drugs, a precedent signal for high-value consumables pricing governance.

Three Ophthalmology Signals

Signal One — The Anti-VEGF 8-Year Crossroads

Ranibizumab (Lucentis, Novartis) entered China’s national drug formulary through the 2017 national negotiation round, with formal inclusion under the Ministry of Human Resources and Social Security document No.54 (人社部发 [2017] 54号). [Independently confirmed: NHSA No.147 (医保函 [2019] 147号), 24 September 2019] It has now reached the 8-year threshold stipulated in the 2026 draft renewal rules.

Under the draft rules, drugs at the 8-year milestone face a pricing crossroads. Transferring to common catalogue management locks the current reimbursement price permanently and removes the drug from future annual negotiation cycles. Continuation under simple renewal terms maintains annual markdown exposure but retains pricing optionality, including the possibility of re-entering negotiation if a new indication is approved. The 2026 draft reduces the required markdown for drugs in their fifth or subsequent consecutive agreement year, softening but not eliminating the renewal pathway.

Conbercept (Lumitin, Kanghong Pharmaceutical) transferred to common catalogue management at the end of 2025, the first anti-VEGF drug in China to do so. Its reimbursement price is now fixed. Kanghong’s high-dose variant is currently in Phase III clinical trials; formal approval would create a new application pathway via new indication submission.

Two structural constraints remain constant regardless of which pathway is chosen. First, formulary payment conditions for anti-VEGF drugs include lifetime injection limits per eye, a volume ceiling that restricts long-term franchise growth independently of formulary status. Second, the 2026 draft shows no movement on that ceiling. The 8-year decision for ranibizumab is not a forward-looking planning item. It is a current-cycle question.

Signal Two — Commercial Insurance and High-End IOL

OphthalLogix Analytical Judgement. The following is based on publicly available information and does not represent a statement of current regulatory policy or confirmed direction.

The formalisation of the commercial insurance dual-track creates, in principle, an institutional pathway for premium medical devices, including high-end intraocular lenses. The structural fit is logical: premium IOLs exceed the “protect the basics” threshold of basic insurance; they represent precisely the category of high-value innovation that the commercial insurance pathway was designed to accommodate.

The execution barrier is the same one documented on the drug side, and it applies with equal or greater force to devices. Hospital procurement dynamics, invoice-discount mismatches, and physician incentive structures have impeded the drug-side pathway despite sustained policy backing. The device side begins this journey without the preparation time the drug side has had.

The revolving door for high-end IOL is institutionally open. It is not currently turning. The medium-term question for IOL market access teams is whether the drug-side execution constraints will resolve in 2026, because their resolution creates the infrastructure conditions that would make device-side access viable. If they do not resolve, commercial insurance for premium IOL remains a logical possibility with unresolved operational barriers.

Signal Three — The Access Gateway Principle

OphthalLogix Analytical Judgement.

China’s medical insurance system covers approximately 1.4 billion enrolled individuals. Formulary inclusion is not one access pathway among several; it is the primary channel through which a product reaches the majority of China’s hospital market at volume. Companies that work the formulary-procurement dual track systematically, formulary positioning, procurement selection, quality and price differentiation, clinical evidence accumulation, hold a structural market access advantage that private-pay and commercial insurance channels cannot replicate at scale.

For IOL companies specifically, this formulary consultation does not alter the operative 2026 strategy framework. Formulary position, procurement selection plus product differentiation remains the primary architecture. The commercial insurance channel is a watch item, not a redeployment target. What this consultation does change: the window to make the anti-VEGF 8-year crossroads decision is this cycle.

Key Implications

For ophthalmology companies managing anti-VEGF portfolios. The 8-year threshold under the 2026 draft renewal rules is not a future scenario. Ranibizumab is at the threshold. The choice between common catalogue management (permanent price lock, no annual renegotiation) and simple renewal (markdown exposure, retained optionality on future indications) requires a position before the formal submission window opens in June.

For market access teams tracking commercial insurance as a device access pathway. The revolving door exists in legal text. Execution infrastructure does not yet support it. Track whether the drug-side barriers, discount flow recognition, hospital listing friction, and physician incentive adjustments resolve in the current formulary cycle before treating commercial insurance as an actionable device pathway.

For strategic teams monitoring pricing signals. The red-yellow label formalisation for competitive drugs is a forward signal for high-value consumable pricing governance. Provinces including Tianjin, Fujian, and Heilongjiang have applied analogous warning mechanisms to medical device procurement. Formalisation at the national formulary level is a precedent signal, not a confirmed extension, that similar logic may migrate to device-side price management.

— OphthalLogix Intelligence

Subscribe now

This analysis is based on publicly available policy documents and independent analytical judgement. It does not constitute legal, regulatory, or investment advice. Policy details are subject to change following the public consultation process; verify against official documents before acting on this content. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.

intelligence@ophthallogix.com · www.ophthallogix.com

In April 2026, China’s IOL market was compressed from both ends simultaneously. The clinical floor rose: two NHC notices in 17 days elevated surgery standards from advisory guidance to statutory obligation across every tier of the public system. The commercial ceiling tightened: price governance moved from policy text to four-day operational execution. The market that existed on 31 March no longer exists on 30 April.

The clinical floor: two notices, 17 days

On 13 April, NHC’s Medical Administration Bureau issued No.117 国卫办医政函 [2026] 117号, China’s first mandatory national standard for adult cataract surgery. Three advisory documents issued between 2019 and 2025 were superseded. Deviation without documented clinical justification now carries regulatory and legal exposure, not merely professional risk.

Seventeen days later, on 29 April, NHC issued No. 134 国卫办医政函 [2026] 134号, a targeted enforcement directive to 24 provinces, requiring county hospitals to establish full-cycle IOL traceability as a hard compliance requirement. The 17-day interval between the two notices is the policy signal: central authorities had already assessed that county-level voluntary compliance would be insufficient. NHC inspection visits are expected no earlier than Q3 2026.

The commercial ceiling: 4,375 products, four days

In March 2026, Liaoning’s public resources trading centre implemented price governance for 4,375 non-selected device products, including intraocular lenses, over four calendar days. The formal compliance window was 30 days. Tianjin’s simultaneous release of a three-colour price transparency consultation draft on 25 April confirmed this is not a single-province initiative: cross-provincial price linkage is now operational infrastructure, not future policy.

The 16 April IOL procurement list update reinforced the same dynamic. Johnson & Johnson’s EDOF toric at RMB 9,090 is not a market-clearing price; it is a competitive foreclosure price. Products not selected in Round 1 face passive exclusion through hospital information system configuration, with an approximately 70-day supplementary pathway and a 95 per cent volume fulfilment requirement.

What No.9 does — and does not — do

State Council Document No.9 国办发 [2026] 9号, published 14 April, established China’s first national drug pricing framework since 2015. Market commentary has interpreted this as a signal of equivalent protect

ion for innovative medical devices, including IOLs. It is not. The document’s legal scope is limited to drugs. IOL manufacturers cannot cite Document No. 9 in pricing arguments until a parallel device-side instrument is issued by NMPA and NHSA. No such action has been initiated.

Key Implications

→ For companies with VBP-selected IOL status: county hospital procedure volumes will contract in the short term whilst traceability infrastructure builds. The consolidation is a transition, not a structural decline; volume will migrate toward compliant facilities.

→ For companies without selected status, cross-provincial listing compliance now requires active management across at least four governance regimes simultaneously. The policy-execution gap between the 30-day formal window and the four-day operational reality leaves no margin for passive monitoring.

→ For all market participants: Document No. 9 does not apply to devices. A strategy based on that interpretation is built on an incorrect legal premise. Act on verified document text.

The April 2026 Policy Delta Log, covering all eight signals, a structured no-significant-movement section, and a forward-looking monitor list, is attached to this post. The Data Reference section is formatted for direct use in internal reporting.

OphthalLogix Delta log April 2026

228KB ∙ PDF file

Download

Download

OphthalLogix Delta log Presentation April 2026

274KB ∙ PDF file

Download

Download

— The OphthalLogix Intelligence Team

Subscribe now

This article is published by OphthalLogix Intelligence for informational purposes only. It does not constitute legal, regulatory, investment, or medical advice. Policy information reflects publicly available sources as of 30 April 2026. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.

intelligence@ophthallogix.com · www.ophthallogix.com

On 13 April 2026, China’s NHC published its national adult cataract surgery operating standard. Seventeen days later, it issued a separate directive to health authorities in 24 provinces ordering county-level hospitals to implement it. The second document is not a clarification. It is a correction signal, and it tells you precisely where the IOL market is about to come under pressure.

I. The Policy: What Notice No. 134 Requires

On 29 April 2026, NHC’s Medical Administration Bureau published Notice [2026] No. 134 (国卫办医政函 [2026] 134号), addressed to provincial and autonomous region health authorities across 24 jurisdictions. The list is deliberate: Hebei, Shanxi, Inner Mongolia, Liaoning, Jilin, Heilongjiang, Anhui, Fujian, Jiangxi, Henan, Hubei, Hunan, Guangdong, Guangxi, Hainan, Sichuan, Guizhou, Yunnan, Tibet, Shaanxi, Qinghai, Gansu, Ningxia, Xinjiang, and the Xinjiang Production and Construction Corps. Beijing, Shanghai, Zhejiang, Jiangsu, and Shandong are absent. This is a targeted intervention in the provinces where county-level medical capability is structurally weakest.

The notice imposes four requirements on county hospitals. First, establish a quality management system covering the full surgical pathway, pre-operative assessment, intraoperative procedure, post-operative follow-up, and internal audit cycles. Second, comply in full with the adult cataract surgery operating standard issued on 13 April (国卫办医政函 [2026] 117号 / Notice [2026] No. 117). Third, implement full-cycle traceability for all implantable devices, including intraocular lenses, and prohibit the reuse of single-use instruments. Fourth, accept oversight from provincial blindness prevention technical groups and participate in NHC-organised national inspection visits.

The document sets no specific remediation deadline. What it does announce is that NHC will organise inspection visits. That announcement is the operative pressure mechanism.

II. The Seventeen-Day Gap

NHC issued Notice No. 117 on 13 April. It published Notice No. 134 on 29 April. The interval is 17 days.

Ministries do not issue targeted enforcement follow-ups 17 days after a national standard unless they have already concluded that the standard will not be implemented without additional administrative force. The sequencing is the signal. NHC has assessed that county-level health systems in these 24 provinces will not reach compliance through normal policy diffusion, and has acted accordingly.

This is the policy-execution gap made visible. National technical documents, once issued, do not automatically translate into changed behaviour in a county hospital in Guizhou or Yunnan. The pathways through which a ministry notice reaches an operating theatre, provincial relay, institutional awareness, staff training, system procurement, workflow change, each introduce delay and attenuation. Notice No. 134 is NHC’s acknowledgement that those pathways, left alone, will not close the gap within an acceptable timeframe.

The commercial implication follows directly. The county-level IOL market is not in a phase of smooth expansion, temporarily complicated by a compliance requirement. It is in a phase of forced supply-side consolidation: facilities that cannot demonstrate compliance will reduce or suspend elective procedures; those that can will absorb the volume that shifts toward them.

III. County Hospitals: The Structural Context

The following reflects OphthalLogix’s market observation and analytical judgement, not verifiable regulatory data.

Talent and capability hierarchy

County hospitals sit at the base of China’s medical capability hierarchy. Talent flows toward provincial and city-level institutions; county facilities receive what the pipeline does not retain. An ophthalmologist operating at a county hospital in a recipient province has typically completed a training rotation at a higher-tier institution and returned to serve a local population, building experience more slowly, with less peer access, and against limited annual procedure volume. Annual case volume at some county facilities is modest enough that technical proficiency accrues slowly. This is not a criticism of the individuals involved; it is a structural feature of how China’s medical training system concentrates human capital.

Infrastructure baseline

Medical record systems at the county level remain heterogeneous. Many facilities operate in a transitional state between paper-based and digital records, with hospital information systems that were not designed for the kind of implant-level data linkage that IOL traceability now demands. Prior to Notice No. 134, IOL management at the point of care was, in much of this market, a manual process: physical product labels attached to surgical notes, without binding to patient records or connection to procurement and insurance settlement systems.

Full-cycle IOL traceability, connecting procurement, inventory management, surgical use, and medical insurance reimbursement through a continuous data trail, is an infrastructure project for most of these facilities, not an administrative update.

Compliance behaviour and the inspection dynamic

OphthalLogix assessment: The inspection announcement creates a de facto transition window. County facilities now know that NHC visits are coming; they do not know exactly when. That uncertainty functions as a compliance accelerant for facilities with the institutional capacity to respond, and as a deferral mechanism for those without. Historical patterns in Chinese healthcare regulation suggest that enforcement consequences accelerate sharply once the first inspection findings are publicised, regional administrations move quickly once a comparable facility has been cited. The hospitals that remediate in this window face administrative review. Those that do not face inspection findings with consequences that can include procedure restrictions and medical insurance designation reviews.

IV. Three Commercial Decisions This Reshapes

Volume forecasts require a new variable

Short-term county-level cataract procedure volume may contract. Facilities that cannot demonstrate compliance will reduce elective cases during remediation, not because patient demand has changed, but because the compliance risk of continuing without a functioning quality system has increased. Those patients do not disappear; they wait, or they travel to a city hospital. Neither outcome translates to near-term volume growth in the county segment.

Medium-term, as facilities reach compliance, volume will return, and likely grow beyond pre-policy levels, as quality-gated county hospitals become credible referral destinations within the primary care network. The timeline, however, is tied to inspection outcomes and institutional remediation capacity, not to demographic projections. Sales forecasts that model county-level IOL volume as a linear function of population ageing and procedure expansion, without a compliance progress variable, are currently overstated for the next 6 to 12 months and potentially understated for the 24 to 36 months that follow.

Distributor economics are shifting

IOL traceability at the county level changes the value equation for distributors. A distributor capable of supporting hospital staff through the operational requirements of compliant device management, documentation workflow, data linkage guidance, and staff orientation holds a competitive position that did not exist before 29 April. A distributor whose value is purely logistical faces a different conversation with hospital procurement teams operating under compliance pressure.

This restructuring will not happen uniformly. Provinces with stronger administrative follow-through on NHC mandates will move faster; others will calibrate to the inspection risk they actually perceive. The companies that understand this geography, which provinces will move quickly, which will interpret enforcement at the margin, will allocate distributor development resources more precisely than those that treat the 24-province directive as a single market event.

The execution window is open now

Between Notice No. 134’s publication on 29 April and the onset of NHC inspection visits, county-level commercial teams have a finite window to assess their covered hospitals. Which facilities have functioning IOL traceability systems? Which are remediation candidates? Which are at procedural risk? This is an information advantage that compounds quickly.

OphthalLogix assessment: Inspection visits are expected no earlier than Q3 2026, though no schedule has been announced. The approximate two-month gap between the notice date and a plausible inspection onset is a working window, not a margin of comfort. Teams that complete this assessment before inspections begin can anticipate volume disruption and position accordingly. Teams that begin after the first inspection findings circulate will be responding to events rather than leading them.

V. Key Implications

Twenty-four provinces of the county-level IOL market have entered mandatory quality compliance. This is not a transient regulatory moment; it is a structural reset of which facilities can credibly operate a cataract programme.

The 17-day interval between Notice No. 117 and Notice No. 134 is the most informative data point in both documents combined. It signals that NHC entered this process with an assessment already formed: county-level compliance, left to self-organise, would not arrive.

Short-term procedure volume contraction in the county segment is the probable near-term outcome of this policy sequence. Consolidation around compliant facilities is the structural one. For IOL companies, the competitive variable in the county segment has shifted: price alone no longer determines which products and distributors retain access. Traceability capability, distributor service quality, and hospital compliance support are now part of the equation.

The companies that recognised this before the inspection cycle began are positioned differently from those that recognised it after.

— The OphthalLogix Intelligence Team

Subscribe now

This analysis is based on publicly available regulatory documents. It does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; verify before acting. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.

intelligence@ophthallogix.com · www.ophthallogix.com

Since our first note on the three reimbursement regimes governing China’s intraocular lens market, the most common question has been direct: what do the hospital economics actually look like inside each regime?

This document answers that question.

We have put together a 13-page diagnostic on how the market operates. It is structured to be useful to a strategy team in the first ten minutes and rigorous enough to defend to a finance function in the first hour.

What it contains

An executive summary of the three regimes and their commercial logics, Beijing’s hard cap with explicit patient top-up, Guangzhou’s post-March-2025 proportional reimbursement, and the DRG/DIP bundling now operating in Shanghai, Zhejiang, Jiangsu, Sichuan and Chongqing.

The provincial reimbursement map across eight markets with full source references.

The 4th national VBP anchor prices and the regional roll-out rules.

A hospital P&L model showing why the trifocal is uneconomic under DRG, a RMB 13,520 to RMB 6,680 hospital loss per case against a RMB 7,000 bundle.

The strategy matrix (region × product × verdict) and the P0/P1 regional priorities.

Two observations on physician behaviour that current market narratives miss: the U-shaped preference function under DRG, and dispute-aversion as a second, unnamed driver of IOL selection.

How to apply

The document is available on application, free of charge. We review each request individually before sending, this keeps the circulation traceable and the readership verified.

To apply, email intelligence@ophthallogix.com with the subject line “Diagnostic — application” and include five pieces of information: full name, work email (on a company domain), company name, job title, and LinkedIn profile URL. We use these to confirm we are sending the document to the right kind of reader. We aim to respond within three working days.

Substack subscription is open for readers who want to follow ongoing work on this and adjacent topics. Use the Subscribe button at the top or bottom of this post.

Key Implications

Companies managing intraocular lens portfolios across multiple Chinese provinces face three distinct commercial logics, not one. A strategy that treats China as a single market will misprice risk in at least one regime. The policy-execution gap is widest in DRG provinces, where the bundled payment structure makes premium IOLs structurally uneconomic for hospitals, a RMB 10,000-per-case loss that no amount of promotional effort will close without a policy carve-out. The immediate priority for any organisation with premium IOL exposure in China is to classify each target province by regime type before committing next quarter’s resources. This document provides the province-by-province framework for that classification.

— The OphthalLogix Intelligence Team

Subscribe now

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.

intelligence@ophthallogix.com · www.ophthallogix.com

China’s VBP procurement framework locks in prices for selected intraocular lenses. For non-selected IOL products and device categories outside the framework, a cross-provincial price linkage system has been tightening since early 2026. In March, it executed its first full sweep: 4,375 products, including IOL, 62 companies, and a four-day decision window. In April, four more provinces moved.

I. What Cross-Provincial Price Linkage Does to Non-Selected IOL Products

For IOL products inside the VBP framework, Zeiss trifocal toric at RMB 18,388, Alcon multifocal toric at RMB 12,996, J&J EDOF toric at RMB 9,090, the price is locked by the procurement agreement for the contract period. For IOL products outside it, non-selected products from companies that did not win or did not participate, the question is what mechanism sets the price floor.

The answer is a national minimum listing price enforced through cross-provincial linkage. Any product listed in one province at a price lower than its current listing elsewhere creates a new national reference. The enterprise must report the new price to all other provinces within a defined window, 30 natural days in most jurisdictions, 20 working days in Jiangsu and Ningxia, and adjust its listings accordingly. The national medical insurance information platform enables real-time cross-province price comparison.

The commercial implication: regional pricing architecture, maintaining higher list prices in premium markets whilst accepting lower prices in volume markets, is structurally incompatible with this system. A price concession made in one province is, within the reporting window, a price concession in every province.

For the IOL category specifically, when Liaoning executed a price governance sweep in March 2026 that explicitly named the intraocular lens category, every price confirmed or declined in that exercise became a data point visible to every other provincial platform. The IOL market now operates under a dual pricing architecture: selected products at locked VBP prices, and non-selected products under cross-provincial linkage pressure. The space between these two regimes is narrowing.

II. The March Execution: What Four Days Looked Like for 62 Companies

In March 2026, Liaoning’s provincial public resources exchange centre issued a price governance notice under Liaoning MHSB Notice on Reforming Centralised Sunshine Listing and Procurement (辽医保规 [2024] 1号), 20 August 2024, targeting non-selected products and products above the VBP price ceiling. The exercise covered four categories: joint replacement, orthopaedic spine, intraocular lenses, and sports medicine. Total scope: 4,375 products across 62 domestic and international enterprises, including major multinational manufacturers’ names.

The notice characterised the exercise as the execution of the national healthcare insurance authority’s price governance priorities, a provincial implementation of a national directive, not a local initiative.

The operational timeline was compressed. Liaoning issued the governance notice on 20 March. Enterprises were required to log into the procurement system and confirm or decline by 24 March, four calendar days. Results were published on 25–27 March. New prices took effect on 31 March.

OphthalLogix assessment: The four-day decision window is the operationally significant data point, not the 4,375 product figure. Four calendar days do not allow a complex pricing decision involving multiple provinces, global pricing implications, and management approval chains. Legal and compliance teams can assess regulatory risk in that window; pricing teams cannot model multi-province implications; management cannot obtain global approvals. The practical outcome: most enterprises accepted the adjusted price, because declining and being delisted carries a greater long-term risk than accepting the reduction. The concession was made not because it had been strategically evaluated but because the window for strategic evaluation had closed.

For IOL companies, this creates a compound problem. Non-selected IOL products already face passive exclusion from public hospital procurement; HIS systems at most hospitals are configured to display only selected or viewed-as-selected products at the clinical ordering point. Now, non-selected products that do maintain listing access face cross-provincial price compression with effectively no decision window. Procurement exclusion plus price governance is not additive. It is multiplicative.

III. Tianjin’s Draft: Price Transparency at the Management Level

Tianjin’s Municipal Healthcare Security Bureau published a consultation draft on 22 April 2026: Tianjin’s consultation draft on medical device listing procurement (《关于深入推进医用耗材挂网采购有关工作的通知（征求意见稿）》), with public comment accepted until 6 May 2026 at 18:00. The document is confirmed on ylbz.tj.gov.cn. This is a consultation draft; its rules carry no legal force until a final version is published with an effective date.

The draft’s principal mechanism is the “three-colour nine-segment line” (三色九段线): a visualisation tool built into Tianjin’s municipal procurement platform since at least 2015, now being codified in regulation. The system displays each device’s current listing price against the distribution of comparable product prices across the city’s purchasing institutions, segmented into low, medium, and high zones. Products in the high-price segment are flagged at the point of procurement review.

Key rules in the draft for non-VBP products: listing price must not exceed the lowest provincial listing price nationally; products without listings elsewhere must provide cost calculations; products with no platform transactions for one continuous year have their listings automatically revoked. VBP-selected products are listed at the VBP-selected price and are not subject to the transparency mechanism’s pricing pressure.

OphthalLogix assessment: Completing VBP procurement volume targets is the binding constraint on hospital procurement committees; it is tied directly to medical insurance fund surplus retention, institutional performance assessments, and management accountability. The three-colour mechanism operates within, not above, that constraint. Its real function is not to override the procurement priority but to serve as a negotiation and audit instrument for everything outside the VBP volume obligation: non-selected products, above-quota purchasing, and categories not yet subject to national procurement. Some hospitals have already incorporated the platform’s price-zone data into their own procurement rules, using the displayed lowest price as the default reference in tender documents. The mechanism has moved from a guidance tool to an institutionalised constraint at the facility level. For non-selected IOL products attempting to maintain hospital access through the viewed-as-selected pathway, this means the price comparison with selected alternatives is now visible, documented, and auditable at the formulary decision point, not as a suggestion, but as a procurement rule the committee is accountable for.

IV. Four Provinces in April: The Pattern

Guizhou (黔医保发 [2026] 7号, 10 April 2026, effective 1 June): national minimum price mandatory, 30-day dynamic adjustment requirement, price verification from at least three provincial platforms required.

Sichuan (川药招 [2026] 1号, 4 January; price updates under 川药招 [2026] 63号, effective 1 April): national minimum listing price as mandatory reference, verified across all provinces, 30-day update window.

Liaoning April actions (16th batch routine price adjustments, effective 29 April, one-week transition): this batch covers general consumables under the 辽医保规 [2024] 1号 framework. It is separate from the March IOL-specific governance sweep but operates under the same price linkage architecture.

Tianjin (consultation draft, 22 April, comment deadline 6 May): architecture-level document codifying the three-colour transparency mechanism and full national price linkage rules for all listed products.

The provinces are not innovating independently. They are implementing a national framework on provincial timelines. The concentrated activity in April 2026 across Guizhou, Sichuan, Liaoning, and Tianjin, following Liaoning’s March IOL execution, indicates that cross-provincial price governance has moved from policy design to operational deployment.

V. Policy-Execution Gap: 30 Days on Paper, Four in Practice

The formal policy text across multiple provinces specifies a 30-day window for enterprises to report and adjust prices following a new national low. Hebei and Hainan cite 30 natural days. Jiangsu and Ningxia compress to 20 working days. Zhejiang allows approximately 14 days.

The policy-execution gap is the distance between these formal windows and the reality of a point-name governance exercise. When a provincial bureau identifies a cohort of non-compliant products and issues a batch correction notice, the administrative timeline is not bound by the formal reporting window. Liaoning’s four-day window in March was not a deviation from policy; it was an exercise of administrative discretion within the framework of the 辽医保规 [2024] 1号.

For pricing teams, this gap has a direct operational implication. A compliance function built around the formal 30-day window will fail when the actual execution uses a point-in-time model. The relevant planning assumption is not “we have 30 days to respond” but “we may have four days, and those four days may begin without prior warning.”

VI. Key Implications

For market access teams managing non-selected IOL portfolios in China: the architecture described here was already executed in March across the IOL category. Immediate action: audit whether your China pricing architecture assumes any meaningful price differentiation across provinces for non-selected IOL products. If it does, that architecture is not compatible with the current direction. Cross-provincial price linkage compliance needs to be built into your listing decision process, not handled reactively after a governance notice arrives.

For companies with selected IOL status (Zeiss/Shanghai Pharma, Alcon, J&J/CR Guangdong, AiBo): VBP selected prices are protected during the current contract period (ending mid-2026). The three-colour mechanism and cross-provincial linkage do not directly compress selected prices within the agreement period. The indirect risk is in the next procurement cycle: the price data generated by the transparency mechanism now forms part of the baseline for future negotiations.

For companies without selected status relying on the viewed-as-selected pathway: the pathway offers formulary access but not quota credit. The three-colour mechanism makes the price comparison between your product and selected alternatives visible at the management level. The combination of no quota credit, management-level price visibility, and cross-provincial linkage pressure is a structurally difficult position. The question is not whether to act but whether action before the third procurement year (mid-2026) is still possible.

For investors: the March Liaoning exercise is the clearest available signal of how non-VBP price governance will operate across high-value device categories. 4,375 products, 62 enterprises, four-day window, executed as a national directive. Valuation models that assign meaningful probability to regional price differentiation for non-selected device products in China should be revisited.

Subscribe now

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.

— The OphthalLogix Intelligence Team · www.ophthallogix.com · intelligence@ophthallogix.com

I. What the List Actually Shows

The 20260416 version divides every IOL product into four categories. Selected products competed and won a price-based procurement slot; hospitals must purchase these to fulfil their annual agreement volumes. Viewed-as-selected products did not participate in the original competitive round but have since been added through a supplementary pathway, at a price no higher than the sponsoring company’s existing selected price. Non-selected products competed but did not win, or did not participate. Products outside the scope are explicitly excluded from this procurement exercise.

The premium end of the selected list establishes the price structure that now governs the market:

The non-selected section reveals how many products from major manufacturers currently sit outside the procurement framework. Multiple international and domestic companies have products in the non-selected category, including several with significant portfolios across monofocal and premium segments.

One detail worth noting precisely: Johnson & Johnson has products listed under two separate legal entities, its mainland distributor CR Guangdong (whose EDOF products are selected) and a separate direct entity. The procurement framework treats legal entity and product registration as the unit of analysis, not brand identity. Market access teams that model China exposure at the brand level rather than the entity and registration level will misread their own position.

II. The Public Hospital Market Is Already Decided

The 20260416 update is being published as procurement year two is in progress. Public hospitals in the procurement are required to fulfil at least 95 per cent of their prior year’s actual purchase volumes for selected products before any discretionary purchasing of non-selected products becomes operationally viable. Medical insurance departments actively monitor completion rates and follow up with institutions that fall behind.

The policy-execution gap here is not between what the policy says and what hospitals intend to do. It is between what market access teams assume about physician autonomy and what the system actually permits.

OphthalLogix assessment: Clinical practice within China’s public hospital ophthalmology system has adapted to the procurement list as the default selection framework. The list covers a clinically adequate range across monofocal, toric, multifocal, and EDOF categories, and the overwhelming majority of cataract surgery patients carry medical insurance of one type or another, which in practice fixes the choice to listed products. When non-selected products are discussed with clinicians, the response is typically not opposition but unfamiliarity. Non-selected products have not entered the clinical conversation.

The mechanism behind that unfamiliarity is structural, not personal. Hospital procurement departments configure HIS (hospital information systems) and SPD (supply and distribution) platforms to display only selected or viewed-as-selected products at the point of clinical decision-making. Non-selected products are not visible in the system at the moment a physician places an order. A physician choosing an IOL sees the options the system presents. Options that the system does not present do not exist in clinical practice.

This is passive exclusion, not active rejection. The distinction matters for how market access teams should interpret hospital-level data, and for where commercial effort is directed.

III. “Viewed as Selected” — Two Mechanisms, Two Different Realities

The supplementary pathway is frequently cited as the route through which non-selected premium IOLs maintain hospital access. The mechanism deserves close reading because it operates very differently depending on the status of the company using it.

Products from companies with existing selected status can be added at a price no higher than that company’s existing selected price for the equivalent category. These additions enter the full selected system: they count towards hospital annual procurement quotas, carry the standard medical insurance payment rate, and generate the same compliance credit as originally selected products.

Products from companies without selected status may be listed at a price no higher than the category average of selected products. However, they receive only one benefit: exemption from non-selected product classification in hospital performance assessments. They do not generate procurement quota credit. Hospitals must still fulfil their volume obligations through genuinely selected products before these products become operationally accessible.

OphthalLogix assessment: For companies with selected status, Johnson & Johnson added a new EDOF product to the list within approximately 70 days of regulatory approval. This is deliberate product management. The pathway allows J&J to extend its procurement footprint for each new product launch without re-entering competitive bidding, as long as the price remains within its existing selected band. For companies without selected status, the pathway offers hospital access without quota credit. It is a survival mechanism, not a growth instrument. The distinction is the difference between a strategic tool and a temporary lifeline.

Companies without selected status that are currently relying on the viewed-as-selected pathway should treat that position as time-limited. The third procurement year, beginning in mid-2026, will determine whether the pathway remains available as the overall framework matures.

IV. RMB 9,090 — What That Price Actually Represents

The 20260416 list shows Johnson & Johnson’s EDOF toric lens at RMB 9,090, and the preloaded version at RMB 9,290. These did not enter through competitive bidding. They entered through the supplementary pathway, at a price J&J chose to accept.

The question of whether 9,090 is a market-clearing price or a strategic price has a clear answer: it is a strategic price.

Alcon entered the fourth national procurement batch with pricing that brought trifocal and premium lens categories from above RMB 20,000 to below RMB 10,000. The overall average price reduction across the IOL category was approximately 60 per cent. J&J’s decision to enter the supplementary pathway at 9,090 was a response to that price floor, not an independent assessment of what the product is worth.

The logic is competitive foreclosure. By accepting 9,090 as the entry price for its EDOF toric, J&J secured procurement access and simultaneously set the reference price that any subsequent EDOF entrant will be measured against. Any competitor seeking to enter the supplementary pathway for an EDOF toric product must price at or below the average of existing selected prices in that category, a figure that is now anchored, in part, by J&J’s 9,090.

OphthalLogix assessment: In China’s premium IOL market, Johnson & Johnson holds a leading position in EDOF development, clinical training infrastructure, and real-world adoption. Its clinical credibility in this segment is ahead of other manufacturers. The 9,090 price point benefits from that credibility; it is not priced for parity with lesser-regarded products. At this level, J&J’s margin on the Chinese public hospital market is almost certainly under structural pressure. This product is priced to hold market access, not to generate the returns that its global pricing history would suggest are sustainable.

The commercial question is not whether 9,090 becomes the reference price. It already is. The question is whether your company’s products are on the right side of that reference when the third procurement year framework is confirmed in mid-2026. A company that delays this decision by two procurement years will find the reference price set, the quota volumes committed, and the clinical relationships in place for competitors.

V. Key Implications

For MNC market access teams: the 20260416 list is not static. The procurement office updates it periodically; this version follows several prior updates. Teams should verify current product registration status against the list, confirm which legal entity is submitting which products in which category, and audit whether any non-selected products relying on a viewed-as-selected position are still meeting the price conditions required. The entity-level split in the J&J data is a prompt to do this audit at the registration level, not the brand level.

For companies with selected status: the supplementary pathway is available now and should be used actively. Every product that gains selected or viewed-as-selected status before the third procurement year’s framework is confirmed strengthens the position. The window between regulatory approval and supplementary listing, approximately 70 days in J&J’s case, is a workable timeline if the process is prepared in advance.

For companies without selected status: the honest assessment is that the public hospital market for listed IOL categories is largely decided. The policy-execution gap runs entirely against non-selected products: the procurement quota must be filled first, the HIS system does not display non-selected options, and clinical teams have adapted their practice to the list. Commercial activity directed at public hospital formulary access for non-selected premium IOLs will generate diminishing returns. The more productive question is whether a pathway to selected or viewed-as-selected status is achievable before the third year closes.

For investors: the list structure is stable enough to model. The premium IOL segment has a confirmed price range from RMB 784 to RMB 18,388, with the high end representing Zeiss trifocal toric. The EDOF category has an established anchor at RMB 9,090. The policy-execution gap that matters for returns is not the gap between selected and non-selected — that is resolved. It is the gap between stated procurement price and actual margin, which at these price levels is not publicly disclosed by most participants and warrants independent verification.

Subscribe now

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.

— The OphthalLogix Intelligence Team · www.ophthallogix.com · intelligence@ophthallogix.com

On 14 April 2026, the China State Council Office Notice Guobanfa [2026] No. 9 ( 国办发[2026] 9号 ), Opinions on Improving the Drug Price Formation Mechanism. It is the first national framework document on drug pricing issued under the authority of the State Council Office since 2015, when China abolished government-set drug prices. At a policy briefing the following day, NHSA Director of Drug Pricing and Procurement, Wang Xiaoning, stated that volume-based procurement “does not cover innovative drugs.” That statement, combined with the document’s text, has been widely read as a turning point for innovation pricing. The reading is directionally correct but operationally premature, and for companies in the device and consumable sector, the distance between the signal and an executable rule is significant.

What the Document Actually Says

Three mechanisms are established or formalised by the document:

A first-launch pricing mechanism for new drugs. Newly listed drugs will operate under an enterprise self-assessment system, with companies setting prices based on clinical value, market conditions, competitive landscape, and social affordability. For high-level innovative drugs with high clinical value, the document supports pricing commensurate with high investment and high risk at the time of launch, with relative price stability maintained “for a defined period.” The duration of that period is not specified in the document and was not defined at the press briefing. It is an intentionally open parameter, subject to forthcoming implementation guidelines.

A commercial insurance pathway for innovative drugs. The document formally incorporates commercial health insurance as a payment channel for innovative drugs, and references the accelerated implementation of the Commercial Health Insurance Innovative Drug List. The first edition of that list, covering 19 drugs including CAR-T therapies and an Alzheimer’s treatment, took effect on 1 January 2026. Products on the list carry three administrative exemptions: they are excluded from hospital self-pay ratio assessments, excluded from VBP-substitute monitoring, and excluded from DRG/DIP episode payment calculations.

A normalised VBP framework targeting mature, multi-supplier drugs. The document defines the scope of volume-based procurement as drugs that are “multi-sourced and long-established.” This is the basis for Wang Xiaoning’s statement that VBP does not cover innovative drugs. It is a clarification of scope, not a new exemption. VBP was designed for commoditised products and was never intended for first-launch innovations. What is new is the explicit national codification of this boundary.

From the original text: “For high-level innovative drugs with high innovation and high clinical value, [the State Council] supports pricing commensurate with high investment and high risk at the time of market launch, and maintaining relatively stable prices for a defined period.”

(Original: “对创新程度高、临床价值大的高水平创新药，支持在上市初期制定与高投入、高风险相符的价格，在一定时期内保持价格相对稳定。”)

The Two Execution Gaps That Matter

Gap one: the innovation recognition standard does not yet exist. The document supports pricing protection for drugs with “high level of innovation” and “high clinical value”, but the criteria for making that determination are described as “under development.” No operational definition has been published. No self-assessment template is available. Until these criteria are established and the first-launch price mechanism is implemented, companies cannot use this framework to defend a price. The signal is real; the instrument is not yet ready.

Gap two: the device sector requires its own document. The policy-execution gap is most significant for companies in the medical device and consumable sector. Document [2026] No. 9 has explicit legal force over drugs. Its application to medical devices requires independent action by NMPA and NHSA, separate regulatory instruments that have not been initiated as of the document’s publication. Companies in ophthalmics, orthopaedics, cardiovascular devices, or any other high-value consumable category cannot cite No. 9 as the basis for a pricing or procurement argument. The logic may transmit; the rule has not.

Commercial Insurance: A Third Channel, With Limits

The commercial insurance mechanism deserves attention separately from the VBP question, because it is already operational rather than pending.

The first Commercial Health Insurance Innovative Drug List is live. As of 1 January 2026, the list covers 19 drugs. Several cities have moved quickly: Shenzhen’s Huimin Bao product has incorporated all 19 drugs into its 2025 coverage; Shantou’s version raises the reimbursement ratio by ten percentage points for hospitalisation involving listed products. In 2024, city-level supplemental insurance and million-yuan medical insurance products combined paid approximately RMB 4.5 billion in innovative drug costs, a growing but still narrow figure relative to basic insurance’s RMB 460 billion expenditure on negotiated drugs.

Device coverage exists in parallel. Several Chinese commercial health insurance products already cover high-value medical consumables outside the basic insurance scope. Jiangsu’s 2026 Medical Huibao covers medical-insurance-excluded high-value consumables. Guangzhou’s Suixinbao covers innovative drugs and devices approved under the Greater Bay Area drug and device access scheme. Shanghai’s Lingang Blue Bay Plan covers new consumables not yet in the standard insurance catalogue. These products operate outside the national Innovative Drug List framework but serve the same structural function: bridging the gap between basic insurance coverage and clinical reality.

The structural limit. The Commercial Innovative Drug List is a reference document, not a mandate. Insurance companies incorporate listed products voluntarily. Coverage penetration varies significantly across cities and products. For device companies, no equivalent national list currently exists; the device-side commercial insurance coverage is city-specific and product-specific, without a central framework to accelerate adoption.

What This Means for Multinational Healthcare Companies

Companies such as Alcon, Zeiss, Johnson & Johnson, Novartis, and Roche operate across drugs, devices, and consumables simultaneously. Document [2026] No. 9 affects these portfolios asymmetrically.

For the drug portfolio: the strategic window is opening. A multinational company launching an innovative drug in China for the first time now has a national framework that explicitly supports early-launch pricing commensurate with R&D investment. This changes the global launch sequencing calculation, China has historically been excluded from or deprioritised in global launch waves because of its price-suppression environment. Document [2026] No. 9 is the first formal signal that this environment is changing. The practical tools are not yet available, but the policy direction is set at the State Council level.

For the device and consumable portfolio: the current path is unchanged. Innovation in medical devices is recognised and encouraged at the regulatory level through NMPA’s Special Review Pathway for Innovative Medical Devices. But that recognition does not currently confer pricing protection or VBP exemption. Device companies that want to position a product as innovation-protected need to watch for a separate NMPA/NHSA instrument that would mirror the No. 9 logic on the device side. Until that instrument exists, the pathway remains: regulatory approval, market listing, procurement platform registration, and, for high-volume standardised products, eventual VBP inclusion.

For the ophthalmic portfolio specifically: premium intraocular lenses occupy an instructive position. Trifocal and EDOF IOLs were included in the fourth national VBP round for high-value consumables in 2023, which means they have already been treated as multi-supplier, market-mature products rather than protected innovations. Reversing that classification for existing products would require a separate policy intervention. What Document [2026] No. 9 creates, however, is a policy framework that a genuinely novel ophthalmic device, one meeting NMPA’s innovation criteria and not yet subject to VBP, could eventually benefit from, if and when device-side rules are established. The window is not open yet, but the policy architecture that would open it is now visible.

Key Implications

State Council Office Notice Document [2026] No. 9 is the most significant national drug pricing document since China’s 2015 price liberalisation, and it establishes an unambiguous policy direction: high-value innovation warrants protected pricing at launch. For pharmaceutical portfolios, the strategic implication is immediate; China’s historical role as a late or low-priority launch market requires reassessment. For device and consumable portfolios, the policy-execution gap is substantial: the document’s logic does not transfer automatically, and the separate regulatory instruments needed to make it operational on the device side have not yet been drafted. Companies with mixed drug-device portfolios should evaluate their China innovation pipeline through both lenses simultaneously, and monitor NMPA and NHSA for device-side implementation signals that would operationalise the No. 9 framework for high-value consumables.

Commercial Execution Brief

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.

— The OphthalLogix Intelligence Team

Subscribe now

China’s medical device listing system is no longer a one-time registration. On 17 April 2026, Zhejiang province’s drug and device procurement centre published notice 11330000MB18470516/2026-03450, suspending seven medical device products from online trading due to classification code non-compliance. Three weeks earlier, Shenzhen’s public resources trading centre issued a separate notice requiring non-selected IOL and sports medicine products to adjust listing prices to comply with provincial price ceilings, with products failing to respond within the objection window facing delisting. These are not isolated events: since January 2025, over ten provinces, including Hebei, Shandong, Shaanxi, Hunan, Heilongjiang, Jiangxi and Hubei, have initiated listing data governance actions. China’s device listing system is transitioning from a one-time registration to an active, ongoing compliance obligation.

What Changed, and Why It Matters

The policy-execution gap here is straightforward: most manufacturers entered China’s provincial listing platforms when their products launched and have not revisited those filings since. The regulatory assumption, ‘once listed, always listed’, is no longer valid. Listing status is now subject to active monitoring, price comparison across provinces, and classification code validation. Failure on any of these dimensions triggers suspension.

Three Conditions That Now Trigger Suspension

Provincial rules vary in detail but converge on three suspension triggers:

1. Price-linkage overdue

A lower listing price appears in another province. The manufacturer must update the local price within 30 calendar days. Non-update confirmed = suspension, typically 1 year.

30-day window. No other violation required.

2. Inaction on platform migration

Hubei’s 2025 system migration required all listed products to confirm data bindings by a set date. Products with no confirmation were excluded from the new platform automatically.

Deadline-driven. Silent = suspended.

3. Classification code mismatch

The Zhejiang April 2026 suspension: products were listed under a procurement category that did not match their registered device classification. Seven products from one manufacturer (peripheral vascular intervention devices, not ophthalmic), all suspended on the same notice.

Discovered via platform data governance audits.

The Zhejiang case involved peripheral vascular intervention devices, not ophthalmic products. Its significance for IOL manufacturers is structural: it demonstrates that classification code mismatch is now an active suspension trigger alongside the two previously observed mechanisms. The enforcement infrastructure does not distinguish by therapeutic area.

Zhejiang adds a fourth dimension: category-wide exposure. Under Zhejiang’s price-linkage rules, if a manufacturer has six or more products in a single category with non-compliant linkage filings, the entire category is suspended, not just the specific products. For manufacturers with broad product portfolios, one compliance gap can remove an entire device line from the province’s procurement platform simultaneously.

Why This Is Not Indirect for IOL Manufacturers

A common assumption is that high-end intraocular lenses, multifocal, EDOF, toric premium, are largely insulated from listing compliance issues because their principal revenue comes from out-of-pocket patients rather than insurance reimbursement. This assumption is incorrect in a specific, consequential way.

Listing is not a precondition for insurance payment. It is a precondition for any public hospital procurement. A product that is not entered into a province’s healthcare procurement sub-system cannot be ordered by a public hospital, regardless of whether the patient intends to pay out of pocket. In clinical practice, this means a surgeon has no pathway to recommend a product to a patient if it does not appear in the hospital’s billing catalogue, not because of clinical judgment, but because the administrative channel does not exist.

This is not theoretical. In ophthalmic clinical practice before national VBP implementation, the standard workflow was as follows: before a physician could present any IOL option to a patient, whether single-focus, toric, or multifocal, the product had to be entered into the hospital’s billing catalogue. A product absent from that system could not be priced, could not be consent-documented, and could not be ordered. The physician’s judgment about what was clinically appropriate was constrained entirely by what appeared in that catalogue. A listing suspension does not reduce a product’s visibility to surgeons. It removes it.

Zhejiang’s medical security bureau has built real-time digital monitoring of IOL procurement execution across its public hospitals, publishing compliance rates at the institutional level. The infrastructure for detecting listing anomalies is already operating. The April 2026 suspension is a routine output of that infrastructure, not an exceptional enforcement action.

The Precedent: What Happened to Zeiss and an IOL Import Agent

Two cases define the outer boundary of this risk. In October 2025, the national high-value device joint procurement office cancelled Carl Zeiss Meditec AG’s VBP selection status for its bifocal non-toric IOL product (registration number: 国械注进20153161147) after a quality inspection found the product’s spectral transmittance did not meet the required standard. The suspension cascaded across multiple provinces, including Shanghai, Zhejiang, Guangdong, Ningxia and Guangxi. The lesson: listing status is not product-level, it is enterprise-level. A quality or compliance event affecting one SKU generates platform-wide risk flags for the brand.

In early 2023, an IOL import agent, Hangzhou Xiehe Medical Supplies Co., Ltd (杭州协合医疗用品有限公司), acting as the domestic representative for an Indonesian manufacturer’s IOL product, voluntarily withdrew from a Shanghai municipal IOL procurement after winning the bid at RMB 989 per lens. Under Shanghai’s rules, this triggered a two-year suspension of all that company’s IOL products from Shanghai procurement and listing applications, effective February 2023 to February 2025. One decision: two years of market exclusion across an entire product category.

OphthalLogix Assessment: Who Is Exposed, and What to Do

Listing compliance rules are not drafted to disadvantage foreign manufacturers specifically. But their practical impact is uneven based on execution capacity, not intent.

Manufacturers with dedicated, China-based market access teams that actively monitor provincial price databases, track platform migration deadlines, and audit product classification codes are relatively advantaged as smaller or less-resourced competitors are cleared from platforms. The governance trend is accelerating the consolidation of market access capacity at established players.

The countervailing risk: large multinational manufacturers with broad product portfolios face disproportionate exposure to Zhejiang’s category-wide suspension rule. A multi-SKU ophthalmic portfolio is precisely the structure most likely to carry the volume of non-compliant linkage filings that trigger a category suspension. Size and breadth are not a shield here; they increase the surface area for compliance gaps.

The self-audit window is now. Zhejiang’s April 2026 public notice closes on 23 April. If your products are listed in Zhejiang, the question of whether any of them fall under the categories subject to active governance is answerable in minutes on the provincial platform, and the cost of discovering a problem now is a fraction of the cost of receiving a suspension notice.

Key Implications

China’s medical device listing system shifted in 2025–2026 from passive registration to active compliance maintenance. Manufacturers affected are all entities with products on provincial procurement platforms, both foreign and domestic, but the practical burden falls heaviest on those without dedicated market access monitoring. For IOL manufacturers specifically, the listing-suspension risk is not indirect: a suspended product disappears from the hospital procurement channel regardless of whether the end patient is paying out of pocket. The immediate action is a platform audit of active listing status, price-linkage compliance, and product classification accuracy across key provinces, prioritising Zhejiang and Guangdong, given their demonstrated enforcement activity in April 2026.

Subscribe now

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.

— The OphthalLogix Intelligence Team

The document landed quietly on 13 April. National Health Commission Office Notice 【26】No. 117, the Adult Cataract Surgical Operating Standard (2026 Edition), was published on nhc.gov.cn and forwarded to every provincial health authority in China. Most industry observers treated it as clinical housekeeping. That reading is incorrect.

This piece explains why the Standard is a structural market event, and what the execution gap between policy text and clinical reality means for the IOL market over the next 12 to 24 months.

I. The Legal Category Shift: From Recommendation to Obligation

China’s ophthalmology practice has operated for years under a layered stack of expert consensus documents and clinical guidelines, all advisory, none binding. The 2019 Expert Consensus on Multi-focal IOL, the 2023 Clinical Guidelines for Adult Cataract Surgery, and the 2025 Expert Consensus on Presbyopia-correcting IOL shaped practice but created no enforceable obligation on hospitals or physicians.

The 2026 Standard is different in kind. Issued under the NHC’s administrative authority, it is a regulatory norm, not an academic recommendation. It binds provincial health commissions in quality oversight, informs hospital accreditation, and establishes the reference standard for adverse-event adjudication.

A hospital that deviates from the Standard without documented clinical justification now carries regulatory and legal exposure it did not carry before 13 April.

II. Three Structural Changes That Matter Commercially

Premium IOL categories now have a statutory chapter. The Standard’s Part III dedicates four subsections to IOL selection: IOL classification, monofocal IOL, toric IOL, and presbyopia-correcting IOL, the last of which covers multifocal, trifocal, EDOF, and enhanced monofocal designs. This is the first time a Chinese administrative regulation has explicitly codified presbyopia-correcting lenses as a recognised category with dedicated operating standards. Hospitals now have an official compliance basis for implanting premium lenses that did not exist in any prior binding document.

Pre-operative assessment and documentation requirements are now obligations. The Standard specifies systematic pre-operative evaluation across biometry, corneal topography, and patient communication. The pre-operative workup required to justify a premium IOL implant is now documented, traceable, and auditable. This raises the minimum capability bar for any facility offering a premium lens pathway.

Operating theatre standards are codified. Part VI sets requirements for air cleanliness, layout, humidity, ventilation, equipment, and infection control. Best practice moves to a mandated standard.

III. The Execution Gap

The Notice tells provinces to “organise implementation”, with no unified deadline. Based on comparable NHC standard rollouts, tier-one markets (Beijing, Shanghai, Guangdong, Zhejiang, Sichuan) will move within months. Secondary and western-province markets will take 12 to 24 months.

This is a market-segmentation event disguised as a regulatory document. Compliance capability, equipment, trained staff, and documented processes will determine which facilities can credibly offer a premium IOL pathway, not administrative intent.

IV. Four-Layer Impact

Access layer: Premium IOL implantation now has an official compliance basis. Hospital formulary submissions can reference Part III directly, reducing procurement committee friction. Immediate to 3 months.

Pricing layer: The Standard provides the clinical rationale for premium pricing. Value-analysis committees now have an administrative document that distinguishes premium surgery from standard cataract extraction. 3–6 months.

Payment layer: The NHC’s clinical documentation framework could, in future DRG/DIP 3.0 refinements, support differential reimbursement coding for premium procedures. This is analytical inference, not confirmed policy linkage, but the simultaneous movement of both policy tracks is worth noting. 6–18 months.

Behaviour layer: For hospitals building premium cataract programmes, the Standard provides an implementable clinical template that accelerates capability diffusion in second-tier cities. 6–24 months.

V. What This Means for Manufacturers

The Standard is brand-neutral but not capability-neutral.

For international manufacturers, such as Alcon, Zeiss, and Johnson & Johnson Vision, the Standard reinforces the value of existing training infrastructure and clinical evidence packages. These manufacturers are positioned to help tier-one hospitals build compliant premium programmes quickly.

For domestic manufacturers, the Standard creates a clearer regulatory roadmap for premium product positioning. A domestic player that invests in Standard-aligned training and pre-operative assessment tools could compress the brand credibility gap faster than the historical trajectory suggests.

VI. A Clinical Observation Worth Adding

Premium IOL outcomes depend on patient selection, surgical technique, and expectation management in roughly equal measure. The Standard’s emphasis on documented pre-operative assessment addresses a real and persistent problem: patients entering a premium IOL consultation arrive with heterogeneous prior knowledge, product comparisons from online platforms, peer recommendations, and brand associations that often bear a limited relationship to clinical suitability.

Manufacturers who build Standard-aligned patient communication tools, covering functional outcome expectations, adaptation timelines, and differences between premium categories, will have a genuine commercial differentiator. The value is risk reduction for the hospital, not marketing material.

VII. The One Decision This Forces Now

For any commercial team with China premium IOL exposure: determine whether your hospital submission packages, formulary justification materials, and physician training programmes explicitly reference the Standard’s relevant chapters. They should. The Standard is now the compliance anchor.

For investors: a structural uncertainty has been resolved. Premium IOL surgery in China is now administratively legitimised. The regulatory grey-zone question has been answered.

—OphthalLogix Intelligence Team

OphthalLogix continues to track the market weekly. Please subscribe if you are interested in the articles in OphthalLogix.

The commercial execution brief (stakeholder action frameworks, geographic prioritisation) is available to subscribers via request.

Commercial Execution Brief

This report is for informational purposes only and does not constitute professional advice. OphthalLogix accepts no liability for decisions made based on this content.

Over the past twelve months, the Chinese intraocular lens market has settled into three coexisting reimbursement regimes. Winning prices from the 4th national VBP round have become binding payment standards. Enforcement has begun.

We have compiled a short reference PDF that captures the current state of the landscape in three pages: the four-sentence summary we would take to an HQ meeting, the 4th VBP anchor price table, and the four policy developments of the past twelve months.

The PDF is free to download below. No sign-up required to read; subscription is open if you want to follow ongoing work on this topic.

China IOL Reimbursement Landscape

— OphthalLogix Intelligence Team

This report is for informational purposes only and does not constitute professional advice. OphthalLogix accepts no liability for decisions made based on this content.

Most descriptions of the Chinese intraocular lens market open with a national number: annual cataract procedures, average selling prices, and premium penetration rates. The numbers are not wrong. The market they describe, however, has quietly disappeared. There is no single Chinese IOL market any longer. There are three, and the gap between them is wide enough to matter.

Regime A · Beijing. Hard cap, with a legitimate escape valve.

Beijing caps IOL reimbursement by lens category, most recently RMB 1,835 per lens, under Beijing MSA [2020] No. 28. Patients may, however, legitimately pay the delta to a premium lens against a signed consent form. The mechanism exists on paper and is referenced in current reimbursement notices.

Regime B · Guangzhou. The reform of March 2025.

On 10 February 2025, the Guangzhou Medical Security Administration issued notice [2025] No. 1, removing the IOL reimbursement cap and moving to proportional payment. Guangzhou is, at the time of writing, the only tier-one Chinese metropolitan market to have done so. It is the single largest reimbursement change we have recorded in the past twelve months.

Regime C · DRG / DIP bundling.

Shanghai, Zhejiang, Jiangsu, Sichuan, Chongqing and others have moved cataract care into DRG or DIP case bundling. Under these regimes, the lens becomes a cost item inside a fixed case payment rather than a separately reimbursable consumable. That distinction, on its own, is enough to change the commercial logic of any IOL above the bundle’s implied lens allowance.

The 4th VBP anchors · binding for the next two to three years.

The 4th national volume-based procurement round is the second fact on which any current analysis of this market has to rest. The winning prices are now the payment standard in every province that has published an implementation notice. Any delta above is paid by the patient against signed consent.

Enforcement has begun. In April 2025, the NHSA disqualified an Indonesian supplier from the IOL VBP for breach of its bidding commitments and suspended its eligibility through October 2026, the first public enforcement action since the 4th round opened. Commitments made under VBP should now be treated as enforceable. The renewal window opens in the second half of 2026, and the regulator’s language around the 6th round’s “anchor price” mechanism (January 2026) signals that the next round will not repeat the deep cuts of the last.

Where we go from here

This is the first public release of OphthalLogix Intelligence. We intend to keep tracking this market as it moves, provincial reimbursement updates, VBP enforcement and renewal, and hospital-level execution of the policies already on paper. We will publish further work as the picture clarifies.

If the subject is useful to you, subscribe, and you will be notified when we next publish.

— The OphthalLogix Intelligence Team

This report is for informational purposes only and does not constitute professional advice. OphthalLogix accepts no liability for decisions made based on this content.

OphthalLogix Intelligence tracks the gap between healthcare policy and hospital-level execution in China's ophthalmic device market. We bridge the critical gap between clinical realities and administrative logic.

【Executive Summary: The Shift in Power Dynamics】

China’s ophthalmology market is undergoing a silent but total transformation. The era of monolithic, purely administrative tendering is over. It has been replaced by a sophisticated, hybrid environment, a “dual-track” decision-making process where clinical authority and administrative control constantly negotiate.

The most consequential implication is this: the official tender is merely a "ticket to play." The real procurement decisions are often finalised in the quiet synergy of the operating room and the strategic calculus of the administrative office, long before the first official document is ever published.

【Core Insights: Redefining the China Logic】

1. Efficiency Economics: Time as the True Premium

In China’s high-volume clinical environments, surgical turnover is the ultimate metric. While international players often focus on technical specifications, domestic challengers are winning by optimising “workflow alignment.” By embedding technicians on-site and tailoring support to the surgeon’s rhythm, they create a high switching cost that is independent of the machine’s parameters and entirely driven by clinical efficiency.

2. Consistency Economics: The Moat of Bureaucratic Inertia

Why do hospitals maintain the status quo even when more cost-effective alternatives appear? Because in the Chinese administrative logic, the cost of “doing nothing” is often the lowest. True market dominance is achieved when your presence is so deeply embedded into the hospital’s operational rhythm that “replacing the vendor” becomes bureaucratically inconvenient, expensive, and fraught with administrative risk.

3. The Performance of Alignment

Successful market access is no longer a one-way lobbying effort; it is an art of multi-dimensional alignment. You must simultaneously satisfy the surgeon’s pursuit of clinical excellence and the administrator’s demand for operational security and cost metrics. The winners are those who can navigate the delicate friction between informal negotiation and formal documentation.

【The Bottom Line】

In China, market access is no longer an exercise in compliance; it is a performance of alignment.

Future premiums will not be commanded by the “Imported” label alone. They will be earned by those who prove they understand the surgeon’s heartbeat and the administrator’s administrative safety better than anyone else in the room.

Please access the detailed brief here:

The Hidden Procurement Ecosystem

For business inquiries: ophthallogix@gmail.com

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China's healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.